Grand FDA nod and approval for drug for heart transplant patients

by Medindia Content Team on  March 31, 2006 at 7:35 PM Drug News
RSS Email Print This Page Comment
Font : A-A+

Grand FDA nod and approval for drug for heart transplant patients
In a relief FDA, the U.S. health regulators, gave their nod to the first new drug in nearly a decade to prevent organ rejection in heart transplant patients.

The drug, Astellas Pharma Inc.'s Prograf, is already cleared to prevent rejection of liver and kidney transplants.

Dr. Steven Galson, head of the FDA's Center for Drug Evaluation and Research said, "The doctors who perform approximately 2,200 heart transplants in the U.S. each year will now have a new option for enhancing successful outcomes. Prograf works by suppressing the body's immune system, which can attack new organs it senses as foreign objects."

In one study of U.S. patients, 93.5 percent of patients and their new hearts survived one year after transplant. That rate was similar to what was seen in patients given an older drug, cyclosporine.

Prograf's main chemical ingredient, tacrolimus, is also used in the Japanese company's eczema cream Protopic. so now the drug can have a wider application area and used effectively.


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Cardiac Catheterization Signature Drug Toxicity Heart Healthy Heart Statins Mitral Valve Prolapse Aortic Valve Stenosis Pericarditis 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive